Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective faithfully but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the curing of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set away all of the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire job interview which I came away with a bad opinion of the company.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the know-how and also associated intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) and the very first brand new drug application approval ($five million), and also royalty payments of five % of net sales after commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and multiple therapies, it has this single remedy as well as a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an energetic company with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications and multiple delivering presentations.

Can all this be smoke and mirrors? That’s a question I have been asking myself through the really beginning of my interest in this business. Judging by the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this question.

CytoDyn is a traditional battleground, or maybe some may say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *